COZADD BRUCE C 4
4 · Jazz Pharmaceuticals plc · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Jazz Pharmaceuticals (JAZZ) Director Bruce C. Cozadd Sells 6,000 Shares
What Happened Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), sold 6,000 shares in an open-market transaction on June 1, 2026 at $235.12 per share, generating proceeds of $1,410,720. This was a sale (not a purchase) and therefore is typically viewed as routine insider liquidity rather than a direct bullish signal.
Key Details
- Transaction date and price: 2026-06-01, 6,000 shares at $235.12 each.
- Total proceeds: $1,410,720.
- Filing date: Form 4 filed 2026-06-03 (timely — within the standard two business days).
- Footnote: The sale was made under a Rule 10b5-1 trading plan adopted by Mr. Cozadd on November 26, 2025; the transaction occurred automatically and was non‑discretionary (per footnote F1).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Transaction code: S = Sale.
Context A 10b5-1 plan lets insiders sell according to pre-set instructions, which reduces the likelihood the sale reflects new private information or the insider’s current view of the company. For retail investors, routine 10b5-1 sales are common; purchases (insider buys) generally carry more weight when interpreting insider sentiment.
Insider Transaction Report
- Sale
Ordinary Shares
[F1]2026-06-01$235.12/sh−6,000$1,410,720→ 372,682 total
Footnotes (1)
- [F1]This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.